Munera Maria E. Bedoya-Toro

CIK: 0001400048

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DRMA

Dermata Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

DRMA
Dermata Therapeutics, Inc.
Feb 17, 2026
Purchase(P)
Direct
1K shares at avg. $1.27$1K
DRMA
Dermata Therapeutics, Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
9K shares-
DRMA
Dermata Therapeutics, Inc.
Jan 13, 2025
Award(A)
Stock Option (right to buy)
Direct
8K shares-

		Type	Shares	Price		Ownership
Feb 17, 2026	DRMA Dermata Therapeutics, Inc.	Purchase(P)	1,000	$1.27	$1,270	Direct
Jan 2, 2026	DRMA Dermata Therapeutics, Inc.	Award(A) Stock Option (right to buy)	9,000	-	-	Direct
Jan 13, 2025	DRMA Dermata Therapeutics, Inc.	Award(A) Stock Option (right to buy)	8,000	-	-	Direct

1-3 of 3 transactions

About Bedoya-Toro Munera Maria E

Bedoya-Toro Munera Maria E (SEC CIK 0001400048) files insider reports with the SEC as SVP, Regulatory Affairs of Dermata Therapeutics, Inc. (DRMA).

Signal8 holds 3 ownership filings by Bedoya-Toro Munera Maria E, all Form 4s, filed between Jan 14, 2025 and Mar 17, 2026. Those filings report 3 transactions, from Jan 13, 2025 to Feb 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bedoya-Toro Munera Maria E's filings is in SAN DIEGO, CA.

Recent filings by Bedoya-Toro Munera Maria E

Feb 17, 2026: Open-market purchase of DRMA shares (Form 4, code P).
Jan 2, 2026: Grant or award of DRMA derivative securities (Form 4, code A).
Jan 13, 2025: Grant or award of DRMA derivative securities (Form 4, code A).

Other insiders filing for Dermata Therapeutics, Inc. (DRMA)

PROEHL GERALD T, PRESIDENT, CHAIRMAN, CEO
Van Hoose Kyri K., SVP, CFO
Scott Kathleen D., Director
WIERENGA WENDELL, Director
HALE DAVID F, Director
Nardo Christopher J., Senior VP, CDO

How to read Form 4 transaction codes